Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry typo, should have read in brackets[licenced] not [licencing] sometimes when writing the mind is on turbo while the fingers are a mile behind.
Thanks for the correction.
BLU
Steve: This is my take on those points, as I have mentioned before I was caught up on the last R/S.
In order for Tapimmune to continue as an ongoing entity the largest shareholders had to agree in principle to the restructuring, and then have enough confidence to continue to fund the company through the process.
I also am pondering the effect that another R/S would do to those that believed and allowed the company to continue or simply walk away. I think that it would be very hard for the company to initiate another R/S without overwhelming approval from those shareholders. Which I believe would be very tough.
Point 2: Tapimmune's share price is ludicrous at these levels given their depth of science and imminent catalyst's, without question it should be between $1 and $2 at this point in development.
I have looked at length at most of the Bio's in this space, at fundamentally the same juncture as TPIV that don't have nearly the potential [multi billion dollar markets] I usually go back 5 years and most if not all have within that timeframe seen share prices ranging from $2 to $7. Many have dropped back down, but have seen those lofty valuations and share price.
It is my opinion that by year end we should be in 2 maybe 3 trials, TNBC, Ovarian [the Cancer that took my mother] and the HER2Nue. If any indications of other stocks in this space we will see share prices over minimum $2.
Nasdaq listing has various ways to up list and Tapimmune is putting in place many of the requirements to that end, so far they are right on track to executing what is needed.
I don't know if by year end they can manage to up list, but will be well on their way, and if not by then look for early 2016. But upon initiation of our Phase 11 trials we should garner much attention and think it will be very hard for large institutions to not be buyers. Float is tight and share should move up accordingly.
I still believe that in 2016 with 3 trials ongoing that there is a very good chance, that we will at the very least have a great partnership. But my thoughts are still that we will be bought out at levels no lower than $10.
We must remember that until they finalized the IND of the Folate Receptor science, Tapimmune really had little to no assets [TAP, and Polystart] but still in pre-clinical.
Now they really have a viable company and on the initiation[licencing] of the HER2Nue should be very attractive.
I have spoken with principles of the company and can only say that they seem to be of the same mind.
The market will not be able to ignore the low cost to produce TPIV, it's limited Toxicity not to mention they seem to have the best science to date. A science that can be used in combination with most other applications in development at this time.
Once again who can dispute the findings of Keith Knutson, Edith Perez, Glynn, John who have seen all the data and are still on board.
I also think they will get the grant that they have applied for which will bolster our bottom line.
I am more bullish than ever, for Tapimmune with the licencing of the Folate science [HER2Nue forthcoming] has positioned itself to become a company that may change Cancer as we know it.
Hope that helps.
GLTA
BLU
Stated on website under Pipeline
TPIV200 is their name for the Folate Receptor Alpha technology/science, their Her2nue has 3 applications
TPIV100, TPIV110, TPIV130 has Polystart and TAP combination.
Hope that helps.
BLU
You are "spot on" RK, I believe that is the scenario that will play out, also adding each month under .50 not much $5000 month.
I am trying to find out when they are going to finalize the Her2nue licence, I thought it would be before the Folate Receptor, hoping that it will be announced before the initiation of the Phase 11 TNBC/Ovarian trial.
That would really strengthen our pipeline, and as you say attract the attention of BP. We have no clue but I believe that they are starting to get offers already, upon securing that Her2nue licence the company will be truly validated.
Add TAP and Polystart both proprietary very strong!
BLU
Not only that but TPIV is the only company that has a simple injectable vaccine, as Glynn has stated all others to date must harvest the cells, manipulate them outside the body then re-inject.
Process is very expensive...our very low cost will be the defining factor as Glynn and Keith have stated.
Once they incorporate their patented TAP, and Polystart [not yet patented, but seems to be proprietary]prime and boost technology will make the vaccine that much more effective.
Still hoping that they spin off the Infectious Disease arm to shareholders, as Glynn has stated it increases the production of proprietary antigenic peptides by as much as 4 fold.
They are currently using Polystart for their cancer technology but it has proven to be applicable to their Infectious Disease technology also.
When we enter Phase 11, in TNBC, Ovarian and Her2nue [minimum to date]if indeed do have the best science, at the lowest cost, what would that possibly be worth?
BLU
saffron76: Realistically many Bio stocks in this space have seem at one point or another a minimum MC of approx. 300 mill and/or [$3 to $7] share price.
Now granted that would entail putting into effect the initiation of Phase 11 trials, we are expecting to initiate TNBC, Ovarian within 2, 3 months. With Her2nue expected by years end.
Also I believe that we may see the initiation of Phase 1 with Polystart by years end, I would expect that the start of the TNBC, Ovarian should take and hold us well above $1.
The initiation of the Her2nue I am hoping will move us beyond $2, no one can predict the markets reaction to these catalysts but considering the space we are in $3 to $5 would not seem out of the question in my opinion.
Once again the key to TPIV science in regards to Herception [6 billion year] is TPIV's low toxicity and much more important in regards to the overall space ease and the very, low cost to manufacture and produce.
That in my opinion will be the defining factor. Not only as Glynn has stated to becoming the leader in immunology in this space, but as a defining factor as to partnerships and/or a potential buyout.
Those numbers mentioned seem to be in line with numbers of companies at basically same stage [Phase 11 initiated]
The low cost is massive as no country worldwide I am sure is able to sustain paying 50 to 100 thousand per person to treat these cancers.
Tap and Polystart construct will only enhance/strengthen what we have seen to date, it is hard to determine what SP may become as we have seen the likes of JUNO and KITE at very lofty valuations [$50/$80] with science that seem to be Toxic long term.
So in summary $3 to $5 may seem high in regards to where we stand now but in regards to the overall market and space those numbers may seem relatively small 6 months from now.
If what Glynn, Perez, Knudson and Bonfiglio have said about the data is true we may truly be on the threshold of something remarkable, I myself having studied Tapimmune for many years and am of the same mind as those market leaders.
Hope this helps.
GLTA
BLU
TY, Investor cmz, am here each and every day, hope that all the TPIV supporters are doing well...patience here is the key.
Nothing has negatively changed with the fundamentals of the company to warrant these levels of the stock price, and the company has strengthened many aspects corporately and financially.
So I am still a buyer at these levels although have a large core, I am mostly silent because this is a long term hold for me so simply adding small blocks when price point dictates.
Looking for color on 10Q as mentioned in previous post's.
Thanks and GLTA
BLU
That's old press.
As you all know I am very bullish [long]
I posted about a week and a half ago I was a buyer at .48, and I am a buyer here again, most of my position is much lower but still think that this price is a great value.
Guess we will see by year end if my years of DD on Tapimmune was on point or not.
I bought originally for the science and the lives it will save, any one who does not have that first and foremost..."Good riddance".
Money is secondary for me on this investment, but comforting to know that I am up substantially even at this point.
Patience will be rewarded to all that choose to see further than just the monetary gain here.
Look for 10Q out within the next week or so, expect that we will get much needed color as to what the next few month's hold.
GLTA
Sorry to hear that dave, I am a buyer here at .48.
Patience is the key here, the next two months will validate science and reward those who held.
Price averaging the key, buy when others are running.
GLTA
BLU
Sure you did!
$$$eeker...Good Morning, Still here and still long.
I have not posted lately because I am a long time hold on the stock, I am very comfortable with my position but do not trade the stock.
Some like to trade in and out, but being a Buffett disciple I have leaned over the years to find my investments before the herd arrives then simply accumulate as opportunity presents itself.
I have quite a large position and am not worried about the dips here and there...unless it gets back to .14 to .20.. I still believe Tapimmune may very well be the best Bio stock out there, and we will all be handsomely rewarded over the next 6 month's.
The company is very very solid at this point but until we have some news that warrants my input, I will sit on the sidelines and give my thoughts as new news is disseminated.
I will say that I have unprecedented confidence in the path forward for TPIV, I believe that we are on the cusp of great things. I am not able to remark on future developments but my DD through contacts in the industry regarding Tapimmune [very recently] have been very positive.
As a collaboration we are all of the same mindset,that if as I have already stated the recurrence to disease continues this will be a life changing investment for many.
Once again lets not lose sight, which is easy to do as greed becomes a factor, the main reason I invested was for the potential of the science and the lives it will save.
I believe that Tapimmune's management is working hard to get all their ducks in order for the next move forward.
I think that it is prudent to buy on dips, but be well aware of any selling as the timeline to a potentially big move is not far away.
I simply buy my core position, always a 50% buy initially at what I believe to be the absolutely lowest price I can achieve, then as fundamentals play out buy the other 50% on dips then hold.
This has proven over the years to never let me lose out on the bigger moves, the small trades in and out that people brag about are just that. I have found that, that strategy works out sometimes but more often than not those people are on the sidelines waiting for the low's to come when the big move finally arrives.
I do substantial DD before I make my initial investment and am usually right on my entry price as like TPIV average .23, I can then just sit back and not worry on the day to day BS.
I believe that we will see some more volatility her until we get more news, hard to tell where the base is right now because of the OTC status.
Those that want to increase their positions should buy on any weakness, then just hold, my timeline is still 18/24 months but am hopeing to see $3 to $5 by year end.
Management has a great plan and are executing it very well, their are things going on behind the scenes that we are not aware, they must be very careful here. News given out must not be seen as front running the stock by the FDA.
They have done everything as expected and according to protocol, those patient will be handsomely rewarded.
Hope this helps, any questions I am here everyday.
GLTA
Thanks etradeedge for your kind words, and support happy I am able to help.
Lets reap the TPIV rewards together everyone.
BLU
Thanks bigstocksnbonds, as I have mentioned before your high level of enthusiasm is very refreshing on this board.
Very happy that you will reap the rewards of Tapimmunes science along with the rest of great people on this site.
Beginning to dread weekends because it delays the "upward" movement of our stock...LOL
BLU
Thanks for the Canadian Day "shout out" poor broke bloke, by the way if you are holding Tapimmune stock your going to have to change your "moniker" LOL.
Hope that you have a nice position, as the next two, to three month's should prove very positive for all of us.
Not only may we have the very best science in an outstanding space, but may have the added catalyst and good fortune to be so good that a bidding war will erupt after the Phase 11 announcement's, and the potential soon to be Nasdaq up-list.
How great will it be to see our stock with actual numbers where the Bid and Ask are?
Hope everyone is having yourselves a fantastic Fourth of July weekend.
BLU
tpizzazz24...have a great weekend also.
BLU
tootall...thanks for reiterating those two points, as "cost,and toxicity" will be the two discerning points moving forward as too who has the best overall science.
They are also the two major points that will attract,[or maybe already have] the interest of multiple BP. I would however think that they are prudently waiting for TPIV to officially enter the Phase 11 trials. Within the next two to three months.
I feel that it is not important how many people are further along then TPIV in trials, the more the merrier. For as the science continues to move forward and Polystart and TAP are combined with the antigens, they will make a much more complete science.
And will produce many more potential collaborations, interest must be out there, as we are mere peons and we have all put together that scenario.
Once again each week/month that passes us by with the potential of the patients cancer not recurring brings us closer to that goal. The entering into Phase 11, on two maybe three indications will change this stock in my opinion immediately.
I think that if the stock [closes above $1 today] then continues for the next 8 days, and they are able to bank the cash their credibility will increase substantially.
Have patience everyone, I think we are all well aware that their are those that do not want TPIV to succeed. Hence the difficulty in moving the SP forward to any great degree, despite the fact that many are now aware of TPIV's tremendous potential moving forward.
They/We are very close, frustration will change to exuberance shortly...$1 is just crazy much more validation is forthcoming.
At some point, everyone I believe will "want/NEED" to own Tapimmune.
HAPPY FOURTH OF JULY TO ALL OUR U.S.A PARTNERS...Have a Great holiday weekend.
GLTA
BLU
Excellent post TomP1...that is exactly what is going to make the difference for Tapimmune, opposed to the giants JUNO, KITE etc.
Again patience we will get there, and as others have noted 1 year or two no one will remember these days, when we get a deal along the likes of JUNO and others.
As I have said all along the "cost" factor and toxicity or lack there of will differentiate us from the pack.
Frustrating yes at this point, but I have leaned in life to pursue an achievable goal and live life not so much on the day to day setbacks. But focus on the future goal's you have set, and work each day to make those goals/dreams come to fruition.
18/24 month's will be here in a blink!
GLTA
BLU
All your DD questions should be answered if you read prior posts, but no one can make the decision whether you should buy or not.
Are you in at the low...about $1 short on that front, do you stand to make a great deal of money if you buy on this very nice gift entry point that came today?
My answer would be if I had not been in at .14 [have been around this since methuselah] and was just now doing my DD, I would still be all over this at these prices.
When in your trading experience have you had the opportunity to buy a stock just north of a buck, that may make you high six figures and for some that got in really low, seven.
If the science pans out, and it sure seems to be playing out that way, even at $1.25 you stand to make a great deal of money in the next 18/24 months.
But my friend ...do your own DD
Welcome and GL
BLU
What date was that? You need to give confirmation on a story like that.
I've never seen it that low except before the 1/00 R?S
BLU
Thinking that because the Mayo has done most of the work in the trial's, we may get a break and the FDA will expedite the process.
And the RB [review Board] may look more favorably on the Fast Track, IND and Orphan designation.
BLU
I agree, base around 1.35 it seems so probably consolidation within here and there. But with this one you never know, news out mid to end of next week with more financing and still quite undervalued.
Hard to tell when those on the sidelines decide to pull the trigger for positions.
Long term hold so the daily, doesn't seem to matter so much anymore now that the stock has some validation in the price.
BLU
Just out...old but may stabilize stock today.
No Negative Impact From A Strong Dollar With Small Cap Stocks
.
Accesswire
15 minutes ago
CORAL GABLES, FL / ACCESSWIRE / June 25, 2015 / Many companies and their publicly traded stock have been hurt this year by the stronger dollar. Even gold prices have shuttered as the US currency has gained value in the exchange markets. Retail, energy, the list goes on and on as far as which sectors have been hit the worst. But it hasn't been all doom and gloom for the entire market. Higher volatility trading like that involved with penny stocks has not felt the brunt of this event. In fact many of these companies and their stocks have seen an increase in trading volume as well as price, over the better part of the last two months. Enviro-Serv Inc (EVSV), US Precious Metals (USPR), and TapImmune, Inc (TPIV) have seen positive price movement and increased share volume during the late spring and early summer season.
Envir-Serv targets highly profitable small service companies in the commercial and residential property maintenance industry. Through its subsidiary Xterminate the company has begun to enter the final stages of closing on a franchise deal with Pestmaster Services for control of the Tampa area operations. In working with the franchise, Enviro-Serv has the opportunity to secure much larger contracts including those with the government because Pestmaster Services is a national Franchisor and a dominant player in the Governmental contracts sector for pest control. There are 21,000 pest control companies in the U.S. and only 70 are approved to bid on Government contracts. Based on this data and several key announcements, EVSV shares have rallied from lows of $0.0002 to highs of $0.0015 in recent weeks.
US Precious Metals has also seen an increase in trading activity most notably over the last few days of trading. The company updated the public on its current drilling program, which is underway on its property in Mexico. Based on finding significant mineralization in each of the cores that have been drilled, these are now being assayed by an independent lab. For mining companies, this tends to be one of the final steps in determining if or when operations can begin. Speculation has sparked more attention on the stock as volume skyrocketed to over 4 million shares traded during the first half of the week. Currently trending in a price channel between 0.14 and 0.16, shares of USPR have seen prices as high as $0.20 this month.
The biotech space is hot right now and TapImmune has found a similar trend. What looks to have started in May, the run that this stock has been on has lasted the better part of the last two months. The stock saw lows of $0.165 on May 6 and since then the stock has rallied to highs of $1.71. This week the Company reported the completion of data analysis from patients treated in a Phase I clinical trial. Dr. Glynn Wilson, TapImmune's CEO stated "We are excited by the Phase I results of our HER2/neu vaccine trial. The potential to treat ~85% of breast cancer patients with this HER2/neu therapeutic approach is significant. The successful completion of this HER2/neu vaccine Phase I study and the robust immune responses detected provides TapImmune with a second Phase II clinical candidate and an expanded clinical pipeline for the treatment of breast and ovarian cancer. It also further validates the technology and the approach developed at Mayo Clinic by Professor Keith Knutson."
BLU
Waiting for the first Seeking Alpha article, they are notorious for trying to get cheap shares. Sure they will be out soon with a negative article, so they can get a position.
Like I mentioned before it will be hard to do...who is going to dispute the Mayo, Edith Perez, Keith Knutson and of course Kenneth Dart.
And more important the science.
NASDAQ here we come, Glynn has already had a small interview with the NASDAQ a while back, and to my knowledge the feedback from them was quite positive. I believe that they will welcome Tapimmune with open arms.
BLU
Morning tpizzazz, had it, give me a minute...
HOLD
The stock's total return is expected to be in line with the total return of the relevant country Index or the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis over the next 12-18 months.
18/24 month’s we’ll all be on our yacht’s lol...may take him out to lunch...in like “Belize”
Here's the full press...this guy is sooooo wrong! "HOLD" LOL He obviously has not done in-depth Dd. Can't wait to call him in 3 month's when we are much higher, Hold for next 18/24 months how ridiculous. Simply trying to get a better entry point.
Analyst Brief: TapImmune Won’t Settle for the Moon; How Much Further Will it Fly?
Summary
TapImmune Inc., incorporated on October 22, 1991, is a clinical-stage immunotherapy company. The Company is engaged in the development of peptide, gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease.
The Company combines a set of technologies to improve the ability of the cellular immune system to destroy diseased cells. The Company’s technologies include peptide antigen technologies and DNA expression technologies; Polystart, and TAP. TapImmune is focused on the clinical development and testing of its product candidates.
The Company’s standard therapies for its initial targets in cancer include surgery, radiation therapy and chemotherapy. The Company combines a set of technologies to improve the ability of the cellular immune system to destroy diseased cells. These are peptide antigen technologies and DNA expression technologies, Polystart and TAP.
During the year ended December 31, 2013, the Company has none of its product candidates on the market and are focusing on the development and testing of its product candidates. The Company directs its research and development efforts towards the development of immunotherapeutic and prophylactic vaccine products for the treatment of cancer and protection against pathogenic microbes respectively, using its combined technologies include relevant killer plus helper T-cell peptide antigens, Polystart nucleic acid-based expression system(s) and TAP.
The Company continues to focus its efforts on the development of therapeutic vaccines for applications in cancer treatment while demonstrating the breadth of its technology approach for the development of prophylactic vaccines and its ability to complement approved and emerging products in both cancer therapeutics and prophylactic vaccines against microbes.
TapImmune Inc. has a current market capitalization of $49.28 M with 32.64 M outstanding shares. Its daily average volume traded is 1.73 M shares.
Key Indicators (Annual) Performance (6 months)
Recent News
Shares Outstanding
32.64 M Revenue (FY 2014) Nil
Gross Profit
Nil Net Loss (basic/diluted) -30.88 M
Cash and Short-term Inv
2.64 M Total Debt Nil
PAGE | 2
Information Classification: Limited Access
TAPIMMUNE INC.
JUNE 24, 2015
RATING:
HOLD
1551 EASTLAKE AVE E STE 100
SEATTLE, WA 98102-7402
UNITED STATES
WWW.TAPIMMUNE.COM
Since this company was last covered in mid-May, much has changed for the better. Most importantly, the company was successful in enticing its warrant holders to exercise their option and received an immediate infusion of $2.5 million from its largest institutional investor, Eastern Capital Limited. Eastern capital exercised 5 million warrants at $0.50 per share and in addition, the investor still holds 30 million warrants. If exercised, this could provide TapImmune with an additional and much needed $15 million.
The immediate receipt of this $2.5 million further strengthens the company’s balance sheet and ensures its ability to move towards the initiation of a Phase II trial in triple negative breast cancer in the shortest possible time frame.
Eastern Capital's willingness to purchase unregistered shares of common stock is reflective of their confidence in TapImmune's future. Additionally, the company announced positive Phase 1 clinical data from its Folate Receptor Alpha trial in triple negative breast and ovarian cancer. This trial demonstrated the experimental therapy was safe, well-tolerated and provided a robust immune response.
In addition to this positive news from TPIV, the company’s shares have appreciated almost five fold since the company was last covered. Following a correction in the share price after the initial report was issued, the stock turn on its engines and shot for the moon.
The shares appreciated from a low of $0.24 at the end of May to Tuesday’s close of $1.53, after reaching $1.71 better settling at the close price. However, again the shares are deep in overbought territory and a correction is more than likely to occur in the near future.
Pros
? The company finally has cash to takes it products into Phase 2 trials which, if positive, may send this stock far past the moon and into the next galaxy.
?
Additionally, financing from the company’s largest institutional shareholder speaks a lot about the confidence in TapImmune’s strategy going forward.
Eastern Capital injected an additional $2.5 million to TPIV and has the ability to exercise an additionally $15 million worth of warrants. TPIV’s balance sheet should remain healthy as long as they produce positive results.
Cons
? Though Phase 1 trials were completed successfully, the risk always remains whether the company can deliver on Phase 2 trails. Lots can change from now until the results of these trials are released.
? As mentioned before, because the company’s share price has appreciated so greatly in the past month, the stock is deep in overbought territory and will likely experience a correction in the coming weeks.
Verdict
PAGE | 3
Information Classification: Limited Access
TAPIMMUNE INC.
JUNE 24, 2015
RATING:
HOLD
1551 EASTLAKE AVE E STE 100
SEATTLE, WA 98102-7402
UNITED STATES
WWW.TAPIMMUNE.COM
Since last covered, the company has experienced a price correction before shooting for the stars and reaching a new 2015 high of $1.53. It also fixed its naked balance sheet and was able to raise $2.5 million in cash from its largest institutional investor which will be used for initiating Phase 2 Trials for the company’s flagship immunotherapy.
However, just as it was said in May, the company is very deep in overbought territory and a correction is certainly forthcoming. If you are a holder from before all of the recent buzz, take profits and look to reinvest after the correction. If you have been on the sidelines watching this shoot up, it is recommended you watch for a little longer and look to enter a long position after the upcoming correction.
The TapImmune stock is again recommended a ‘Hold’ and should certainly be kept on the watch list to wait out the correction and enter a long position at an attractive price.
Sources:
1. http://www.google.ca/finance?q=OTCMKTS%3ATPIV&fstype=ii&ei=xj9SVemnH8LFjAHC1oG4Dw
2. http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=TPIV.PK
3. https://ca.finance.yahoo.com/q?s=TPIV&ql=1
4. http://www.tapimmune.com/investors/
5. http://www.tapimmune.com/technology/pipeline/
6. http://stockcharts.com/h-sc/ui
Our Rating System
We rate enrolled companies based on the appreciation potential we believe their shares represent, and the “riskiness” we perceive in our ratings. The business results of those companies “NOT RATED” are often highly dependent on some future event, such as FDA drug approval or the option of a new key technology.
Explanation of Ratings Issued
BUY
The stock's total return is expected to exceed the total return of the relevant country Index average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis over the next 12-18 months.
HOLD
The stock's total return is expected to be in line with the total return of the relevant country Index or the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis over the next 12-18 months.
NOT RATED
Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country Index or the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
SELL
The stock's total return is expected to be below the total return of the relevant country's equity indices and/or the total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
PAGE | 4
Information Classification: Limited Access
TAPIMMUNE INC.
JUNE 24, 2015
RATING:
HOLD
1551 EASTLAKE AVE E STE 100
SEATTLE, WA 98102-7402
UNITED STATES
WWW.TAPIMMUNE.COM
Disclosure: I, Robert Borowski have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it, and I have no business relationship with any company whose stock is mentioned in the article.
You're spot on Cre8, that's why each leg up has been so solid.
BLU
Looks pretty good here, great churn of shares and consolidation in the 1.40/1.50 mark [whoop's have to get used to putting a $1 in front of that $1.40...LOL]
Still think that we have another $1.50 to go to give a fair valuation at this point, after announcement of two maybe three indications into Phase 11 all bet's are off.
BLU
Thanks Cre8tivmynd, appreciate that, it is the combined input of many diverse intelligent minds that are giving this board a full spectrum of scenarios.
Each brings their own unique set of skills, and the puzzle is coming together perfectly...once again money aside, how many loved ones do each of us know that this vaccine may give hope, prolong/change their lives.
BLU
The last DHHS contract for a smallpox vaccine stockpile was worth up to $2.8 Billion, just to add that contract went to SIGA, PHARMATHENE [PIP] contested the award due to the fact that they had an agreement in place to purchase the technology then SIGA reneged.
PHARMATHENE won the lawsuit as I and others thought completely plausible, that was a nice trade...I digress
What I am meandering about is as I have posted before, would be great to spin off the Infectious disease arm to shareholders as a separate entity in view of the terrible 1/100 R/S we had to endure. Have seen it happen before so not out of the realm of speculation.
BLU
Couldn't agree more, and RK your posts, DD, and insight are a real bonus to this board.
Other's that deserve credit are, tootalljones, ash 111, tpizzazz24, Eagle1, Canoepaddler, Cre8tivmynd, Burrhead1 and other's, also a welcome out to some notable newcomers who have also chimed in with some great market insight, Resumeblank, ADVFN_epigenetics, undtrdr, saffron76, 21money21, and not to forget bigstocksnbonds who without question is one "crazy chicken who's exuberance is unmatched.
Apologies to anyone I have missed.
As most know, but to the newcomers, I have been with TPIV for years well versed any questions will be happy to try to answer.
We are pretty much up to date now as many very smart minds of those listed above have dissected most possible scenario's...all of which have us in very good stead.
I myself have broadened my knowledge, by listening to some very smart individual's...thank's.
BLU
Without question he turns off the [lol], "Tapimmune Tap", pun on words, as we actually are turning TAP back on in the science.
Pretty sure that has been his agenda all along, NASDAQ is his main objective at this time, as the trading shows, he has the confidence of the market.
Once again just look at the crazy valuations of the KITE'S and JUNO's when the market fully embraces the science [they yet have too] that's when this get's nut's.
Multi, Multi billion dollar markets and that is just U.S in Europe it may even be expedited, again what could the valuation possibly be.
BLU
Just remember although it seems like this has been an incredible run, truth is at this stage compared to their peers we should have a 200/300 Mill dollar valuation as we speak [share price approx. $3 to $5.
After news of two maybe three indications starting Phase 11 we could easily be priced by the market in the range of IMGN, TNXP,INO,$7 to $12 not to mention the likes of KITE, JUNO down the road think the CEO of Roche may be looking very hard at us right now.
My premise all along is that we would be bought out at minimum of $10, totally possible at $15 to $20 within the next 18/24 month's.
Be patient we have all made great gains by ordinary stock appreciation...but Tapimmune is by no means an ordinary stock/company.
The market has yet to really embrace TPIV, yet we are getting very close to being able to up-list and that would I believe move us into the $7, $12 range as KITE and JUNO and recently ADAPTIMMUNE.
When the market fully digest's the totality of Tappimune's science and the live sit will save, their will be no valuation high enough. That coming from someone that lost mother to Ovarian cancer, many of you have experienced a similar loss I am sure.
Think of the 10's/ 100's of millions that have been in our shoes.
GLTA
BLU
Burrhead, Don't have private message, but to answer your question I live in Ontario Canada in Cottage country it is called the Kawartha's have 2 lakes within 1/4 mile. Country life.
BLU
Hey Gang, Just got in went out walleye fishing this morning at
6 Am, caught 3 walleye [keepers] and 4 bass [smallies] stock looks very solid today.
A great group we have here thanks for driving it up while I was out working hard...lol. Got to go fillet them now.
Dinners on me...who wants fresh fillets and russet fries with barbecued shrimp?
BLU
Stock looked strong today...have a great weekend everyone.
BLU
Exactly Eagle: A little suspect to me, but don't believe anything other than tragic events after vaccinating will change the coarse of this train, and we have already left the station on that front.
Safety has proven so far to not be an issue at all
BLU
Data has proved out safe, and immune responses as per Glynn have gone into the 12 month stage, continued immune responses moving forward are a key.
If they bring out news that immune responses are still "heightened" as Glynn put it, for the next 3, 6, 12 months or so it will surpass Herceptin on all fronts.
Recurrence to disease, percentage of patients that can be treated, Safety/Toxicity, and most important $$$$$$COST!
7 Billion per year Herceptin,...anyone think a Billion dollar valuation is to steep, now seems like we are at about 40/50 mill max outstanding after last warrants.
Possible to still dilute another 50 mill shares to 100 mill and a ten dollar buyout would be dirt cheap, [1 billion]if recurrence holds this is much, much bigger.
A side note, management knows that keeping the upside of $1.00 for the next 9 days is crucial to the plan to up-list [Cash and share value] believe that DART is on board with the forward plan.
Sure seems to at this point, as he has transformed this company in his very short time on board, as others have eluded to, he wants this on NASDAQ more than most and has the means to get us there.
BLU
Let me clarify: That post is no longer relevant, whoever chose to post that as a sticky, should take it down, as it no longer is a valid representation of the company.
The company is "rock solid" today, the mistakes management made in the past are no longer relevant as the new appointee's have turned Tapimmune around, and possibly turned it into one of the best companies in the immunotherapy space today.
What a difference 6 weeks make,not worried about R/S now,since DART's participation [capital infusions]I believe that he, and management have the future of the company well in hand.
That posting was simply to give newcomers insight into the very tumultuous past Tapimmune has endured, "key point endured", I am confident that TPIV will change the world of Cancer as we know it today.
BLU
That comment implies that TPIV share price is at an extreme?
Fundamentals "have" and will prove that to be incorrect, and the resistance points that al were touting for pullbacks at .30,.50, and 70 failed to materialize to any great extent.
Sure there are many that followed that advice and are now on the sidelines not wanting to jump in now, or worse waiting for the great over correction.
This stock should never have been under $1.00 to begin with, manipulation got it down there, and will make millionaires out of those of us that held when all others screamed "sell' the chart says sell!
BLu